Routine examination of serum uric acid levels

Oct 13, 2025 by thesweetdesigns.com 2 views

The Relationship Between Serum Uric Acid Levels and Major Cardiovascular Clinical Events in Acute Coronary Syndrome Patients at Adam Malik Hajj General Hospital in Medan in 2015

Introduction

Acute coronary syndrome (SKA) is a serious medical condition that is a form of clinical manifestation of coronary heart disease (CHD). It is a condition that requires immediate attention and treatment to prevent further complications and improve patient outcomes. One of the key factors that can contribute to the development of SKA is high levels of serum uric acid, also known as hyperuricemia. This study aims to explore the relationship between serum uric acid levels and major cardiovascular clinical events in SKA patients who were treated at the Adam Malik Hajj General Hospital in Medan in 2015.

Background

High levels of uric acid have been found to be associated with an increased risk of cardiovascular disease. This is because high uric acid levels can trigger various pathophysiological mechanisms, including endothelial dysfunction and oxidative stress, which can lead to the formation of atherosclerosis. Atherosclerosis is a condition in which the arteries become narrowed and hardened due to the buildup of plaque, which can lead to heart attacks, strokes, and other cardiovascular events. Therefore, examination of serum uric acid levels can be a valuable prognostic tool in predicting the risk of serious clinical events, especially in patients with SKA.

Research Purposes

The primary purpose of this study is to evaluate the relationship between serum uric acid levels and major cardiovascular clinical events during the hospital treatment period in patients with acute coronary syndrome. This study aims to provide insights into the role of serum uric acid levels in predicting the risk of cardiovascular events in SKA patients, which can inform clinical practice and improve patient outcomes.

Research Methods

This study used a retrospective approach, with a total sampling approach to obtain the required data. The study involved 89 SKA patients who met the established inclusion and exclusion criteria. The data collected included demographic information, medical history, and laboratory results, including serum uric acid levels.

Results

The results of this study showed that the majority of patients who experienced hyperuricemia were men, with an average age of 56.76 ± 9.43 years. Hyperuricemia was more common in acute myocardial infarction groups with the elevation of the ST (IMA STE) segment (62%). Bivariate analysis showed a significant relationship between uric acid levels and the occurrence of acute heart failure (p = 0.007) with a risk ratio (RR) of 2.73, and with major cardiovascular events (p = 0.027) with RR 1,612.

Discussion

The results of this study suggest that SKA patients who experience hyperuricemia have a higher risk of experiencing acute heart failure and major cardiovascular clinical events during hospital treatment. This finding highlights the importance of examining serum uric acid levels as a prognostic indicator that can help in the management of SKA patients. By monitoring uric acid levels, medical personnel can be more alert in taking preventive action to reduce the risk of serious clinical events, thereby increasing the results of treatment and quality of life of the patient.

Conclusion

In conclusion, this study provides evidence of the relationship between serum uric acid levels and major cardiovascular clinical events in SKA patients. The results of this study suggest that hyperuricemia is a significant predictor of acute heart failure and major cardiovascular events in SKA patients. Therefore, examination of serum uric acid levels should be a routine part of the management of SKA patients. This study also highlights the need for further research into the relationship between gout levels and cardiovascular risk, especially among vulnerable populations.

Recommendations

Based on the results of this study, the following recommendations can be made:

Routine examination of serum uric acid levels: Serum uric acid levels should be routinely examined in SKA patients to identify those who are at high risk of experiencing acute heart failure and major cardiovascular events.
Preventive action: Medical personnel should be more alert in taking preventive action to reduce the risk of serious clinical events in SKA patients with hyperuricemia.
Further research: Further research is needed to explore the relationship between gout levels and cardiovascular risk, especially among vulnerable populations.

Limitations

This study has several limitations, including:

Small sample size: The sample size of this study was relatively small, which may limit the generalizability of the results.
Retrospective design: The study used a retrospective design, which may be subject to recall bias and other limitations.
Limited data: The data collected in this study were limited to demographic information, medical history, and laboratory results, which may not capture other important factors that contribute to the development of SKA.

Future Directions

Future studies should aim to explore the relationship between serum uric acid levels and major cardiovascular clinical events in SKA patients in a larger and more diverse population. Additionally, studies should aim to identify other factors that contribute to the development of SKA, such as lifestyle factors, genetic predisposition, and environmental factors.
Frequently Asked Questions (FAQs) About the Relationship Between Serum Uric Acid Levels and Major Cardiovascular Clinical Events in Acute Coronary Syndrome Patients

Q: What is the relationship between serum uric acid levels and major cardiovascular clinical events in acute coronary syndrome patients?

A: The results of this study suggest that SKA patients who experience hyperuricemia have a higher risk of experiencing acute heart failure and major cardiovascular clinical events during hospital treatment. This finding highlights the importance of examining serum uric acid levels as a prognostic indicator that can help in the management of SKA patients.

Q: What are the risk factors for developing hyperuricemia in SKA patients?

A: The risk factors for developing hyperuricemia in SKA patients are not well understood, but it is thought to be related to various factors, including:

Genetic predisposition: Some people may be more prone to developing hyperuricemia due to their genetic makeup.
Lifestyle factors: A diet high in purines, obesity, and physical inactivity may contribute to the development of hyperuricemia.
Medical conditions: Certain medical conditions, such as kidney disease and diabetes, may increase the risk of developing hyperuricemia.

Q: How can serum uric acid levels be used to predict the risk of cardiovascular events in SKA patients?

A: Serum uric acid levels can be used as a prognostic indicator to predict the risk of cardiovascular events in SKA patients. A high level of serum uric acid may indicate a higher risk of experiencing acute heart failure and major cardiovascular events.

Q: What are the implications of this study for the management of SKA patients?

A: The results of this study suggest that examining serum uric acid levels should be a routine part of the management of SKA patients. This can help identify patients who are at high risk of experiencing acute heart failure and major cardiovascular events, allowing for early intervention and prevention of these events.

Q: What are the limitations of this study?

A: This study has several limitations, including:

Small sample size: The sample size of this study was relatively small, which may limit the generalizability of the results.
Retrospective design: The study used a retrospective design, which may be subject to recall bias and other limitations.
Limited data: The data collected in this study were limited to demographic information, medical history, and laboratory results, which may not capture other important factors that contribute to the development of SKA.

Q: What are the future directions for research on the relationship between serum uric acid levels and major cardiovascular clinical events in SKA patients?

A: Future studies should aim to explore the relationship between serum uric acid levels and major cardiovascular clinical events in SKA patients in a larger and more diverse population. Additionally, studies should aim to identify other factors that contribute to the development of SKA, such as lifestyle factors, genetic predisposition, and environmental factors.

Q: How can SKA patients reduce their risk of experiencing cardiovascular events?

A: SKA patients can reduce their risk of experiencing cardiovascular events by:

Maintaining a healthy diet: Eating a diet that is low in purines and high in fruits and vegetables can help reduce the risk of cardiovascular events.
Engaging in regular physical activity: Regular physical activity can help reduce the risk of cardiovascular events by improving cardiovascular health.
Managing medical conditions: Managing medical conditions, such as diabetes and hypertension, can help reduce the risk of cardiovascular events.
Monitoring serum uric acid levels: Regular monitoring of serum uric acid levels can help identify patients who are at high risk of experiencing cardiovascular events, allowing for early intervention and prevention of these events.

Q: What are the potential consequences of not managing serum uric acid levels in SKA patients?

A: The potential consequences of not managing serum uric acid levels in SKA patients include:

Increased risk of cardiovascular events: Failing to manage serum uric acid levels can increase the risk of cardiovascular events, such as heart attacks and strokes.
Reduced quality of life: Failing to manage serum uric acid levels can reduce the quality of life of SKA patients, as they may experience more frequent and severe cardiovascular events.
Increased healthcare costs: Failing to manage serum uric acid levels can increase healthcare costs, as patients may require more frequent and extensive medical treatment.